Active Biotech AB Interim report January - March 2015
April 23 2015 - 1:31AM
Laquinimod
Tasquinimod
-
Results from the Phase III study 10TASQ10 showed
that treatment with tasquinimod reduced the risk of radiographic
cancer progression or death compared to placebo (rPFS, HR=0.69, CI
95%: 0.60 - 0.80) in patients with metastatic castration resistant
prostate cancer (mCRPC) who have not received chemotherapy, but did
not extend overall survival (OS, HR=1.09, CI 95%: 0.94 -
1.28)
-
Further development of tasquinimod for the
treatment of prostate cancer has been discontinued. The
collaboration agreement with Ipsen will accordingly cease.
ISI
Financial
summary
MSEK |
Jan. - Mar. |
|
Jan. - Dec. |
|
2015 |
2014 |
|
2014 |
|
Net sales |
2.9 |
2.1 |
|
10.4 |
|
|
|
|
|
|
|
Operating loss |
-57.4 |
-59.2 |
|
-228.5 |
|
Loss for the period |
-58.0 |
-60.2 |
|
-231.5 |
|
Loss per share (SEK) |
-0.64 |
-0.80 |
|
-3.02 |
|
Cash and cash equivalents |
270.5 |
298.5 |
|
328.5 |
|
For further
information, please
contact:
Tomas Leanderson, President and
CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com |
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
|
Active Biotech AB Interim report
January - March 2015
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1913651
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Actividentity Corp (MM) (NASDAQ): 0 recent articles
More Active Biotech News Articles